| BEYOND THE TARGET |
|
| Year : 2020 | Volume
: 52
| Issue : 2 | Page : 142-149 |
Update on the target structures of SARS-CoV-2: A systematic review
Manisha Prajapat1, Phulen Sarma1, Nishant Shekhar1, Ajay Prakash1, Pramod Avti2, Anusuya Bhattacharyya3, Hardeep Kaur1, Subodh Kumar1, Seema Bansal1, Amit Raj Sharma1, Bikash Medhi1
1 Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
2 Department of Biophysics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
3 Department of Ophthalmology, Government Medical College and Hospital, Chandigarh, India
Correspondence Address:
Bikash Medhi
Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijp.IJP_338_20
Knowledge of structural details is very much essential from the drug-design perspective. In the systematic review, we systematically reviewed the structural basis of different target proteins of SARS-corona virus (CoV2) from a viral life cycle and from drug design perspective. We searched four literature (PubMed, EMBASE, NATURE, and Willey online library) databases and one structural database (RCSB.org) with appropriate keywords till April 18, and finally, 26 articles were included in the systematic review. The published literature mainly centered upon the structural details of “spike protein,” “main protease/M Pro/3CL pro,” “RNA-dependent RNA polymerase,” and “nonstructural protein 15 Endoribonuclease” of SARS-CoV-2. However, inhibitor bound structures were very less. We need better structures elucidating the interactions between different targets and their inhibitors which will help us in understanding the atomic level importance of different amino acid residues in the functionality of the target structures. To summarize, we need structures with fine resolution, co-crystallized structures with biologically validated inhibitors, and functional characterization of different target proteins. Some other routes of entry of SARS-CoV-2 are also mentioned (e.g., CD147); however, these findings are not structurally validated. This review may pave way for better understanding of SARS-CoV-2 life cycle from structural biology perspective.
[FULL TEXT] [PDF]*
|
